EBITDA grew 11% to BRL 2.5 billion in 2024, driven by operational excellence, cost cuts, and business focus. Leverage fell to 4.08x, cash generation surged, and margins improved across both hospital and diagnostics units. JV with Amil and business segregation set the stage for further gains.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.